Synthes Legal Troubles –Again

July 1, 2009 by Michael Ricciardelli · 1 Comment
Filed under: Drugs & Medical Devices, FDA, Fraud & Abuse

wheelchairseatingntsb [Today's Post is by Maansi K. Raswant, a Seton Hall Law student pursuing the Health Law concentration. She is a research assistant to the Center for Health & Pharmaceutical Law & Policy and an intern at the NYC Health and Hospitals Corporation.]

Recently, the Synthes corporation has been garnering a lot of attention, but for all the wrong reasons. A June 17^th indictment comes a little over a month after the New Jersey Attorney General announced that the medical device maker had entered into a settlement agreement for failing to disclose financial conflicts of interests held by physicians conducting clinical trials for its products (see prior post, “Clinical Research: When the Compensation Begs the Answer“). Filed by the United States Attorney for the Eastern District of Pennsylvania, the recent 52-count indictment alleges that from May 2002 to Fall 2004, the Swiss company Norian, and its parent company Synthes, (both based in West Chester, Pennsylvania) conspired to conduct unauthorized clinical trials of Norian XR and Norian SRS, bone cement products used in surgery to treat vertebral compression fractures of the spine. Not only did the trials lack FDA authorization, but the FDA had specifically warned Synthes against using Norian XR for spinal surgery due to safety concerns.

The indictment explains that preliminary studies using human blood in test tubes found that the bone cement products chemically reacted with the blood to create blood clots. In further studies of the prod in a pig, the clots became wedged in the lungs. Despite this knowledge, Synthes continued to market the Norian products for use in spinal surgery, and did not stop doing so until after three patients had died on the operating table. According to the indictment, rather than recall the products following the patient deaths, the company engaged in a cover up by lying to FDA officers during an official inspection in May and June 2004.

The two recent legal actions against Synthes break new ground, and represent significant inroads by prosecutors in the arena of clinical research. Among other remedies, the settlement with the State of New Jersey required Synthes to disclose all relevant financial interests of its investigators on a public website, and barred the company from compensating investigators with stock, a practice the Attorney General called widespread in the industry. The latest indictment contains not just the usual charges against the corporations, but also criminal charges against four corporate executives charged with shipment of unauthorized devices. If found guilty, each executive faces up to a year in prison.

Tags: Anne Milgram, Drug & Device, Drug and Device, FDA, Fraud and Abuse, Health Care Reform, Health Reform, Norian, Synthes

Comments

One Response to “Synthes Legal Troubles –Again”

Trackbacks

Check out what others are saying about this post...

healthranker.com says:

07/01/2009 at 10:04 pm

Synthes Legal Troubles –Again : HEALTH REFORM WATCH…

Medical Device maker Synthes in trouble again–this time with criminal indictments….

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

Recent Posts

Reorganization of UMDNJ to be Implemented this Year

Navigating the New Field of International Health Law, Featuring Gian Luca Burci, Legal Counsel for WHO

Research, the Avian Flu and Bioterrorism

Bill Requiring Licensure of One-Room Ambulatory Surgery Centers In New Jersey Dies in Gov. Christie’s Pocket

Online Graduate Certificate Programs

Professor Frank Pasquale featured in The Record on ‘A Constitutional Right to Health Care’

New Evidence on Smoking Marijuana and Lung Function; Update on New Jersey’s Nascent Medical Marijuana Program

The Good News is that Health Care Spending is Down

Medicare Payment, a System in Need of Fixing

The Needle (Exchange) and the Damage Done

Physician Payment Sunshine Act Proposed Regulations Out

Of provident kidney stones, health insurance and a CT Scan that may have saved my life

Defining Essential Health Benefits

The Nirvana Fallacy Among Health Care Cost Cutters

Money Out of Politics?

Venture Capitalists Complain of ‘Regulatory Challenges,’ FDA Responds

Will Durant, The Story of Civilization, and Immunization and Human Subject Research, or “I Never Promised You a Rose Garden”

A Call for Improved Guidance on Research with Pregnant Women

Secret Prices: Free Market Triumph or Tragedy?

Update Report, Africa Surgery, Inc., Tom Johnson, Jr., Sierra Leone, December, 2011.

Dr. Donald M. Berwick, Formerly of CMS: an Exit Interview Worth Considering

School-based Health Centers, Mental Health Care and the ACA

Recommended Reading: Recent Scholarship on Drug and Device Regulation

Recent Comparative Studies of Health Systems

Health Affairs on Community Development

Constitutional Mortality: Precedential Effects of Striking the Individual Mandate

Still Alive and Well

A Constitutional Right Not to be Bankrupted by Health Care Costs

Does the Fee Imposed by Section 9010 of the Affordable Care Act Apply to Stop-Loss Coverage?

The Global Burden of Stillbirth

Are Fat Taxes All the New Rage?

Places Cited

Posts from Health Reform Watch have been cited by media sources throughout the country, including The New York Times, Washington Post, L.A. Times, Kaiser Health News, The Health Care Blog, NPR's Planet Money Blog, Duke Univ. Med. Center News, American Health Line Alerts, BusinessWeek.com, Concurring Opinions, Balkinization, The New England Journal of Medicine, Harvard's Nieman Foundation for Journalism, Las Vegas Sun, Maggie Mahar, Ezra Klein, Tom Geoghegan, and the official homepage of the Office of the Democratic Majority Leader of the House of Representatives, Steny Hoyer.
Recent Comments
Audio Presentations

Click on the blue links to play, click again to pause:
Hatch-Waxman "Pay for Delay Audio: Panelists included Michael Kades, Attorney Advisor, Federal Trade Commission; Charles A. Gallia, Counsel, Gibbons P.C.; Anastasia Winslow, Assistant General Counsel, Bristol-Myers Squibb; and David Opderbeck, Associate Professor of Law and Director, Gibbons Institute of Law, Science & Technology.
Hunt Lecture: From the original post: During his week-long visit to Seton Hall Law School, Paul Hunt, Professor of Law, University of Essex School of Law, provided several lectures to students and faculty ...Read More
Maizel Lecture: From the original post: A noted expert in the restructuring of health care business debts, both in and out of court, Sam Maizel treated Seton Hall to a one hour crash course on the fiscal crisis ...Read More
PPACA Discussion: From the original post: On Friday, April 9th, Seton Hall was treated to an expert round table discussion on the new health reform measures. Visiting professor Tim Greaney ...Read More
Kaiser
The Commonwealth Fund
- Achieving Equity in the Health System: The Commonwealth Fund's Vulnerable Populations Program
  Vulnerable populations have more difficulty obtaining health care, receive worse care, and experience poorer health outcomes than other groups. This blog post looks at the new Vulnerable Populations program, which aims to help achieve equity in the U.S. health system.
- Incorporating INTERACT II Clinical Decision Support Tools into Nursing Home Health Information Technology
  This Commonwealth Fund–supported study examined some of the steps necessary to incorporate the the INTERACT clinical transition tools into nursing homes' health information technology systems.
- Wellness Incentives, Equity, and the Five Groups Problem
  This Commonwealth Fund–supported study explores the equity concerns associated with wellness incentives, an increasingly popular way for employers to encourage participation in prevention programs, which can both improve workers' overall health and reduce costs.
- Paying for "End-of-Life" Drugs in Australia, Germany, and the United Kingdom: Balancing Policy, Pragmatism, and Societal Values
  This brief analyzes British, Australian,and German policies on coverage of "end-of-life" drugs.
- Bending the Health Care Cost Curve: New Era in American Health Care?
  Health care spending in 2009 and 2010 grew at the slowest rates in 50 years. This startling news was largely attributed to the shrinking economy. In a new blog post, Commonwealth Fund president Karen Davis suggests that lower longer-term projections point to a shift in the health system.
RWJF Health Reform News
- Digital Doctoring
  Among the most common reasons why people come to an emergency room are bouts of heart failure or pneumonia. Note: Viewing this article may require a subscription.
- Study: Hospitals Overpay for Devices
  Some hospitals pay thousands of dollars more than others for big-ticket medical devices such as defibrillators and hip replacements, and a portion of the higher costs could be passed on to the federal Medicare program, a new government report says. Note: Viewing this article may require a subscription.
- Health Care Payers Push Back Against Costs
  In a paper, “Divide et Impera: Protecting the Growth of Health Care Incomes (Costs),” published this month in the British journal Health Economics, I summarize themes touched on here and there in several earlier posts on this blog.
- Taking Another Shot At The Flu Vaccine
  Despite nearly 20 years of recommendations that health workers get flu shots, the most recent data from the Centers for Disease Control and Prevention show that less than 64 percent of them do. Consumer and business groups met in Washington Thursday to show their support for a recommendation from the National Business Group on Health (NBGH) that hospitals re […]
- Cervical Cancer: There's An App for That
  When Mary Jo Payne hears about efforts to educate the public about cervical cancer, she thinks back to her own encounter with the disease at age 38.
ACA Litigation Blog
NY Times Health Policy
- Komen Reverses Stance on Planned Parenthood Grants
  The Susan G. Komen for the Cure foundation apologized for its decision to cut grants to Planned Parenthood for cancer screening and said it would restore the funding.
- National Briefing | Health: Officials Recommend the HPV Vaccine for All Boys
  Federal health officials recommended on Thursday that all boys be routinely vaccinated against infection with human papillomavirus, or HPV.
- F.D.A. Approves Cystic Fibrosis Drug
  The Food and Drug Administration called Kalydeco a “breakthrough therapy” because it treats the underlying cause of the genetic disease, rather than just the symptoms.
- Non-Specialists Expand Into Lucrative Cosmetic Surgery Procedures
  With declining insurance reimbursements, more doctors are expanding their practices to include things like breast augmentation and liposuction paid for out-of-pocket by patients.
- Global Update: Joint Effort Announced Against Tropical Diseases
  Companies, governments and nonprofit organizations are releasing money, access to databases and outreach efforts to counter diseases such as leprosy and guinea worm.
WaPo Health
- Redskin London Fletcher’s fitness regimen
  Let’s say your job is to take off at a sprint, get moving about 20 mph and slam yourself full speed into a brick wall — 60 times in a single afternoon. We’d give you a helmet and lots of padding to protect yourself. Because of the toll this would take on your body, we’d make you do it only once a week. And we’d reward you handsomely. Read full art […]
- Keep your New Year’s fitness resolution without hitting the gym
  This is it. This is the year you finally get in shape, shed those pounds or meet that fitness pledge you made at 11:59 p.m. on Dec. 31. But do you have to build the new you in a hot, stuffy gym, cheek by jiggly jowl with a dozen other sweaty resolutionaries awaiting their turn on the elliptical machine? Read full article >>
- My workplace fitness resolution
  I’m not saying my co-workers are fat. In fact, a fair number of them are toothpick skinny — including, unfairly, the guy who brings in his latest cupcake creation every other day. Many of them are also super-active, always running, biking and yoga-ing in their free time. Read full article >>
- Guys: Stretch now or pay later
  Listen up, ladies, because it’s confession time, and as you may know, this is not my gender’s forte. So let’s get this over with: Although we are bigger, stronger and faster than you are, we must acknowledge that when it comes to flexibility, most of us are pretty much outclassed. We aren’t built like you, and we don’ t bend like you do. Read full […]
- Ways to get kids to eat quinoa
  When people ask me to list my favorite healthy foods, quinoa always tops the list. And not just because the National Restaurant Association named it the hottest trend in side dishes in 2010. My boys think I like quinoa because when it was first discovered it was named “the mother grain.” Yes, I am proud to be a mother myself, but check out all the real […]
Fierce Healthcare
- FDA commish counters industry critics on expert conflict rules
  There's been an ongoing debate in biopharma circles over the impact a shortage of drug experts is having on the FDA's panel review process. But anyone looking for the�agency to welcome changes in the rules governing conflicts of interest--which have been keeping some of the experts at bay--can rule out any support from FDA Commissioner Margaret Ham […]
- Scoring winners and losers in Japan pharma M&A bout
  Japan's biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Now The Wall Street Journal is reviewing the biggest buyers and seeing�who scored the juiciest gains, and�who harvested bitter losses. Astellas�Pharma, which […]
- Idenix gets good news on hep C trial, but can't compete with Gilead
  Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster buyouts, the key focus today is on Gilead's ($GILD) surprise acknowledgement that its new hep C favorite s […]
- AstraZeneca's R&D chief in China lays out $100M strategy
  One of the hottest trends in the global R&D business in recent years has been Big Pharma's huge investment in China. Among all the emerging countries, China's massive, fast-growing economy has been a magnet for drug developers determined to tap a whole new market. Steve Yang, AstraZeneca's vice president and head of R&D for Asia and […]
- Gilead shares surge as hep C drug scores a cure for big patient population
  Gilead Sciences ($GILD) received its first bonus from the monster $10.8 billion deal to acquire Pharmasset ($VRUS) after CSO Norbert Bischofberger told analysts yesterday evening that PSI-7977 combined with ribavirin cured a group of genotype 1 hepatitis C patients after four weeks of therapy. The analysts already knew that the same treatment had performed w […]
- Threshold, Merck KGaA strike $525M licensing deal for promising cancer drug
  The dealmakers at South San Francisco-based Threshold Pharmaceuticals ($THLD) have crafted a $525 million licensing pact with Merck KGaA covering its late-stage cancer drug TH-302. Threshold snagged a $25 million upfront, a promise of $35 million in near-term paydays and a $20 million reward if upcoming pancreatic cancer data come in positive. And the biotec […]
- U.S. funding drop threatens San Diego life sciences industry
  The life sciences job juggernaut in metro San Diego expanded through the ongoing economic downturn and will produce another 6,000 jobs through 2014, according to a new report. But a big drop in government science funding and a continued decline in venture funding could threaten future growth. Ominously, grants from the National Institutes of Health to greate […]
- Is Lilly betting the farm on its high-stakes Alzheimer's gamble?
  Now that the patent cliff has arrived right on time for Eli Lilly ($LLY), the big question this year is whether or not its massive gamble on the Alzheimer's drug solanezumab will pay off. That's Reuters' theme as it delves into the murky science involved in trying to treat the memory-wasting ailment. And even the most optimistic projections ca […]
- AB soars on promising survival data from Phase II tumor study
  Shares of Paris-based AB Science shot up yesterday after the drug developer reported strong efficacy results from a midstage study of its experimental drug for gastrointestinal tumors. The treatment, masitinib, not only outperformed Sutent, it also appeared to be better tolerated. Investigators in the trial divvied up 44 Gleevec-resistant, advanced-stage pat […]
- Czechs beef up investment in biotech research
  The Czech Republic is substantially boosting its investment in biotechnology research, with plans to build a massive research center near Prague set to employ 600 people, the Prague Daily Monitor is reporting. Plans call for spending 2.4 billion crowns (more than $120 million U.S.) on the project, with the investment drawn from EU funds. It will take two yea […]
Boston Globe Health Blog
- MIT professor wins prestigious chemistry prize
  By Carolyn Y. Johnson, Globe Staff Robert Langer, a biomedical engineer at MIT best known for his contributions in the fields of tissue engineering and drug delivery, has been named the winner of the 2012 Priestley Medal, a prestigious prize...
- Daily check up: New York Times points to Mass. public opinion on health care mandate as a model
  In an editorial today, the Times says support for the national mandate could follow the recent trend in Mass. and grow
- Brigham and Women's performs face transplant on woman mauled by chimp
  Jonathan Wiggs / Globe Staff Photo Steve Nash, brother of Charla Nash, who received a full face transplant at Brigham and Women's Hospital late last month, appeared at a press conference today with his wife, Kate. Charla Nash did not...
- Poll: Public supports mandatory physical education
  In a survey of 501 Mass. residents, 87 percent said the state should require 30 min. of physical activity each school day
- Immigrant health care back in court
  Immigrant advocates had hoped for a quick decision, but the state plans to file a motion that would delay the process
LA Times Health Blog
Health Affairs Blog
- What Is “Sustainable” Health Spending?
  As we embark upon a presidential campaign season, we can anticipate many lively debates on the topics of taxation and spending in this nation. As health spending in the Unites States accounts for 18 percent of our gross domestic product – a rate often called unsustainable – it is critical that we be clear-eyed in [...]
- Latest Wonk Review Highlights HA Blog Post On Bay State Reform
  At the Colorado Health Care Insider, Louise Norris hosts the latest edition of the Health Wonk Review. Louise includes Sharon Long’s Health Affairs Blog post clarifying the facts about health reform in Massachusetts. Check out Sharon’s post and all the great posts in Louise’s Wonk Review.
- Trusting Government: A Tale Of Two Federal Advisory Groups
  Americans increasingly distrust what they perceive as poorly run and conflicted government. Yet rarely can we see far enough inside the federal apparatus to examine what works and what doesn’t, or to inspect how good and bad decisions come to pass. Comparing the behaviors of two influential federal advisory bodies provides valuable lessons about how [...]
- Passing The Torch: A Day In The Life Of An Attending Physician
  November 9, 2011. Time fell back three days ago, leaving me one less hour of daylight to enjoy on a gorgeous Indian summer Wednesday. I’m the attending physician on a busy family medicine inpatient service, and it’s been a long week of patient care and meetings. I rush out of the hospital somewhere near 5 pm, [...]
- Health Policy Briefs: Accountable Care Organizations
  In April 2012 a number of accountable care organizations (ACOs) will begin their contracts with the Centers for Medicare and Medicaid Services (CMS) under Medicare’s Shared Savings and Pioneer ACO programs. The latest health policy brief from Health Affairs and the Robert Wood Johnson Foundation provides an overview of ACOs, their origins, and the current […]

Center News, Programs & Papers

Livestream Podcast, Seton Hall Law Review ACO Symposium

Symposium: Implementing the Affordable Care Act: What Role for Accountable Care Organizations?

Distinguished Guest Practitioner Mark Swearingen Lectures on Trends in Healthcare Law Enforcement

Online Graduate Certificate Program in Pharmaceutical & Medical Device Law to Begin in May 2011

New Jersey’s Commissioner of Health and Senior Services Discusses Medical Marijuana and Two Other Regulatory “Case Studies” at Seton Hall Law

The Limits of Disclosure as a Response to Finanacial Conflicts of Interest in Clinical Research

Fourth Annual Student Health Law Conference To Be Held at Seton Hall Law on October 22nd

Seton Hall University School of Law Launches European Healthcare Compliance Certification Programme in Paris

Seton Hall Law Announces Frank Pasquale as the Schering-Plough Professor in Health Care Regulation and Enforcement

Former UN Special Rapporteur Paul Hunt on International Law & Health as a Human Right & the Human Rights Responsibilities of Pharmaceutical Companies

Recording of Sam Maizel’s Discussion of Distressed Hospitals

Recording of Professors Tim Greaney, John Jacobi, Frank Pasquale, and Sidney Watson Discussing Health Reform

Seton Hall Announces Summer Study Abroad International Health Law Program

Online Graduate Certificate Program in Health & Hospital Law to Launch in April 2010

Seton Hall Law School’s Center for Health & Pharmaceutical Law & Policy Issues White Paper Calling for Major Reforms in the Financing and Oversight of Clinical Research

Risks to Directors and Trustees of Health Care & Life Sciences Companies: Corporate Compliance in a Distressed Economy

Third Annual Student Health Law Conference, Friday, October 16th at Seton Hall Law

Position Paper In Support of the “New Jersey Compassionate Use Medical Marijuana Act”

Seton Hall Law School’s Center for Health & Pharmaceutical Law & Policy Releases White Paper Recommending Reform of Drug and Device Promotion

Tags
Accountable Care Organizations ACO Center for Health and Pharmaceutical Law & Policy Chronic Conditions CMS Conflicts of Interest Constitutional Cost Control Drug & Device Drug and Device Electronic Medical Records EMR FDA Health Care Health Care Reform Health Economics Health Law Health Policy Community Health Reform HHS HIT Hospital Finances Individual Mandate Medicaid Medical Malpractice Medicare National Newspapers & Media Obama Administration Pharma pharmaceutical industry Physician Compensation PPACA Prescription Drugs Private Insurance Proposed Legislation Public Health Public Option Public Plan Quality Improvement Reform Rodeo Seton Hall Law State Initiatives Think Tanks Unconstitutional Uninsured
Meta

HEALTH REFORM WATCH

Synthes Legal Troubles –Again

Comments

Trackbacks

Speak Your Mind

Recent Posts

Categories

Health Reform Law (PPACA) Complete Text

News Sources

Noteworthy Blogs

Of Interest

Resources

Wordpress

Places Cited

Recent Comments

Audio Presentations

Kaiser

The Commonwealth Fund

RWJF Health Reform News

ACA Litigation Blog

NY Times Health Policy

WaPo Health

Fierce Healthcare

Boston Globe Health Blog

LA Times Health Blog

Health Affairs Blog

Center News, Programs & Papers

Meta